Arbutus Biopharma Corporation   Report issue

For profit Phase 1 Phase 2
Founded: Burnaby BC Canada (1992)
Status: Left NME R&D (2020)

Organization Overview

First Clinical Trial
2009
NCT00927459
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Arbutus Biopharma Corporation | Tekmira Pharmaceuticals

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adrenocortical Carcinoma (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Hemorrhagic Fever, Ebola (Phase 1)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hypercholesterolemia (Phase 1)

Infections (Phase 1)

Liver Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 11